Takuya Kotani
Overview
Explore the profile of Takuya Kotani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
501
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ikemoto M, Kotani T, Okada K, Matsuda S, Takeuchi T
Immunol Cell Biol
. 2025 Feb;
PMID: 39953927
We recently developed a hybrid protein, tentatively named human MIKO-1 (hMIKO-1), based on the amino acid sequences of human S100A8 (hS100A8) and hS100A9. Human THP-1 macrophages (THP-1m), differentiated from THP-1...
2.
Okazaki A, Matsuda S, Kotani T, Fukui K, Gon T, Watanabe R, et al.
Front Immunol
. 2025 Feb;
15:1450153.
PMID: 39902054
Introduction: This study aimed to identify new clinical phenotypes of microscopic polyangiitis (MPA) using a principal components analysis (PCA)-based cluster analysis. Methods: A total of 189 patients with MPA between...
3.
Matsuda S, Kotani T, Okazaki A, Nishioka D, Masuda Y, Shiomi M, et al.
Arthritis Res Ther
. 2024 Dec;
26(1):221.
PMID: 39702378
Background: This study investigated poor prognostic factors for the relapse of interstitial lung disease (ILD) in patients with microscopic polyangiitis (MPA) after remission induction therapy. Methods: We enrolled patients diagnosed...
4.
Shiomi M, Watanabe R, Matsuda S, Kotani T, Okazaki A, Masuda Y, et al.
Front Immunol
. 2024 Oct;
15:1457202.
PMID: 39416779
Background: Mepolizumab (MPZ) has demonstrated efficacy in clinical trials for eosinophilic granulomatosis with polyangiitis (EGPA); however, few studies compare the disease course between patients treated with MPZ (MPZ group) and...
5.
Shoda T, Kotani T, Koyama M, Yoshikawa A, Wada Y, Makino H, et al.
J Clin Med
. 2024 Oct;
13(19).
PMID: 39407931
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a major complication of rheumatoid arthritis (RA), but effective treatment remains an unmet need in its management. Our aim was to evaluate the...
6.
Sasai T, Nakashima R, Handa T, Yamano Y, Kondo Y, Matsuda S, et al.
Clin Immunol
. 2024 Oct;
268():110372.
PMID: 39357632
Autoantibodies are detected in idiopathic interstitial pneumonias (IIPs) without a clear connective tissue disease diagnosis, and their clinical significance is unclear. This study aimed to identify a novel autoantibody in...
7.
Matsuda S, Kotani T, Oe K, Okazaki A, Kiboshi T, Suzuka T, et al.
Front Immunol
. 2024 Sep;
15:1407633.
PMID: 39346900
Introduction: This study aimed to identify useful clinical indicators for predicting the relapse of interstitial lung disease (ILD) complicated with anti-aminoacyl-tRNA synthetase (ARS) antibodies (anti-ARS-ILD), being treated with prednisolone and...
8.
Kotani T, Saito T, Suzuka T, Matsuda S
Inflamm Regen
. 2024 Jul;
44(1):35.
PMID: 39026275
Mesenchymal stem cells (MSCs) may be effective in treating connective tissue disease and associated organ damage, leveraging their anti-inflammatory and immunoregulatory effects. Moreover, MSCs may possess the ability to produce...
9.
Shiomi M, Watanabe R, Matsuda S, Kotani T, Okazaki A, Masuda Y, et al.
Mod Rheumatol
. 2024 May;
35(1):126-133.
PMID: 38727536
Objectives: To determine the current retention rate of mepolizumab (MPZ) and identify factors associated with drug retention in patients with eosinophilic granulomatosis with polyangiitis (EGPA) in the Kansai multicentre cohort...
10.
Manabe A, Kadoba K, Hiwa R, Kotani T, Shoji M, Shirakashi M, et al.
Mod Rheumatol
. 2024 Apr;
34(6):1185-1193.
PMID: 38564330
Objective: Infections are a critical concern for patients with microscopic polyangiitis (MPA). This study aimed to identify the risk factors associated with serious infections (SIs) and infection-related mortality in patients...